MaxCyte, Inc. has announced preliminary revenue results for the third quarter of 2026, showing a significant increase in revenue compared to the previous year. The company reported that core business revenue reached approximately $8.1 million, marking a 26% rise from Q3 2025. Additionally, MaxCyte has raised its full-year revenue guidance, reflecting a positive outlook for the company and the cell therapy market.
On October 14, 2026, MaxCyte issued a press release detailing these preliminary results and the updated revenue forecast. The company now expects full-year revenue to be approximately $34 million, an increase from the prior guidance of $30 million to $32 million. This includes an expected core business revenue of around $28 million, up from the previous estimate of $25 million to $27 million.
Background
MaxCyte, Inc. is a leading cell-engineering company based in Rockville, Maryland. The company specializes in providing enabling platform technologies that advance the discovery, development, and commercialization of next-generation cell therapeutics. MaxCyte trades on the Nasdaq under the ticker symbol MXCT and falls under the SIC classification of 8731, which pertains to services in commercial physical and biological research.
What the Filing Says
The filing reveals that MaxCyte's preliminary revenue results are based on management's estimates and are subject to change pending the completion of the company's quarter-end closing procedures. The press release states, "Core business revenue of approximately $8.1 million in the third quarter of 2026, an increase of 26% compared to the third quarter of 2025." The company also noted that its Strategic Platform License (SPL) program-related revenue exceeded $1 million, including a $1 million milestone achieved during the quarter.
Impact
This positive revenue report is likely to affect various stakeholders, including investors, analysts, and competitors in the commercial physical and biological research sector. MaxCyte's growth may put pressure on its competitors to enhance their offerings and performance in the rapidly evolving cell therapy market.
What's Next
MaxCyte is scheduled to host its third-quarter earnings conference call on November 10, 2026, where it will provide further insights into its financial performance and strategic direction. This upcoming call will be an opportunity for stakeholders to gain a deeper understanding of the company's growth trajectory and future plans.